Using advanced gene editing to eliminate hepatitis B virus DNA
Official title: Chemically ligated-guide RNA (lgRNA)-based CRISPR/Cas9 gene editing for elimination of hepatitis B virus cccDNA
Funded at Baruch S. Blumberg Institute · NIH-11002268 · Data updated 2026-11-12
This study is exploring a new way to use gene editing to remove the hepatitis B virus from the liver, which could help people with chronic hepatitis B find a potential cure.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baruch S. Blumberg Institute NIH-funded |
| Lab location | 1 site (Doylestown, United States) |
| Project start | January 1, 2024 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $181,875 |
| NIH project number | 5R21AI179930-02 |
| Project ID | NIH-11002268 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with chronic hepatitis B infection.
✕Less likely to help
Patients who do not have chronic hepatitis B or those with acute hepatitis B may not benefit from this research.
What this research studies
This research focuses on developing a new gene editing technology that targets and eliminates the DNA of the hepatitis B virus (HBV) from infected liver cells. By utilizing a chemically ligated guide RNA (lgRNA) combined with CRISPR/Cas9, the researchers aim to improve the efficiency and effectiveness of the treatment. The approach involves optimizing the guide RNA to enhance its ability to edit the viral DNA, potentially leading to a cure for chronic hepatitis B. Patients with chronic HBV infection may benefit from this innovative treatment if it proves successful.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking cure for chronic hepatitis B, significantly improving the quality of life for affected patients.
How similar studies have gone: Previous studies have shown promise in using CRISPR technology for gene editing in similar contexts, indicating potential for success in this novel application.
Where this research is happening
-
Baruch S. Blumberg Institute
Doylestown, United States Active
Researchers
- Principal investigator: Guo, Ju-Tao — Baruch S. Blumberg Institute
- Study coordinator: Guo, Ju-Tao
Related research
Other NIH-funded projects on the same topics.
-
HBV cure clues in people with and without HIV
This project studies how HBV-specific B and T cell responses relate to curing hepatitis B in people with and without HIV.
-
HBV cure factors in people with and without HIV
This project studies how HBV-specific immune cells behave during treatment and whether people with HIV respond differently than those without HIV.
-
HBV prevention in community pharmacies: a first step in a low-resource setting
This pilot project tests whether hepatitis B screening and vaccination can be integrated into everyday community pharmacy services to reach more people.
-
Blood markers to catch early liver cancer in Hispanic people with hepatitis B
This project will see if a blood test can find liver cancer earlier in Hispanic people who have chronic hepatitis B.
-
Early blood markers to find hepatitis B–related liver cancer in Hispanics
This project will use immune-related blood markers to find liver cancer earlier in people with chronic hepatitis B, focusing on Hispanic adults.
-
HBV safety with long-acting HIV therapy for people with HIV
A study to understand how long-acting HIV meds affect hepatitis B in people living with HIV and how to best monitor and protect them.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.